BR112012031485A2 - formas cristalinas de inibidores de quinase - Google Patents

formas cristalinas de inibidores de quinase

Info

Publication number
BR112012031485A2
BR112012031485A2 BR112012031485A BR112012031485A BR112012031485A2 BR 112012031485 A2 BR112012031485 A2 BR 112012031485A2 BR 112012031485 A BR112012031485 A BR 112012031485A BR 112012031485 A BR112012031485 A BR 112012031485A BR 112012031485 A2 BR112012031485 A2 BR 112012031485A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
kinase inhibitors
thieno
pyrazol
pyridin
Prior art date
Application number
BR112012031485A
Other languages
English (en)
Inventor
Doug H Hoffman
Geoffg Z Zhang
Jonathan Miller
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR112012031485A2 publication Critical patent/BR112012031485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

formas cristalinas de inibidores de quinase. sais de citrato de n-(4-(4-amino-70[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}phenil)-n<39>-(3-fluorofenil) uréia e formas cristalinas dos mesmos são ingredientes farmacêusticos adequados para composições farmacêuticas úteis no tratamento de doenças , por exemplo, câncer.
BR112012031485A 2010-06-09 2011-06-08 formas cristalinas de inibidores de quinase BR112012031485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35303810P 2010-06-09 2010-06-09
PCT/US2011/039591 WO2011156464A1 (en) 2010-06-09 2011-06-08 Crystalline forms of kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112012031485A2 true BR112012031485A2 (pt) 2016-11-01

Family

ID=44454811

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012031485A BR112012031485A2 (pt) 2010-06-09 2011-06-08 formas cristalinas de inibidores de quinase

Country Status (18)

Country Link
US (2) US8633217B2 (pt)
EP (1) EP2580220B1 (pt)
JP (1) JP5727598B2 (pt)
KR (1) KR20130112856A (pt)
CN (1) CN103038239A (pt)
AR (1) AR083152A1 (pt)
AU (1) AU2011264902B2 (pt)
BR (1) BR112012031485A2 (pt)
CA (1) CA2802029A1 (pt)
ES (1) ES2536503T3 (pt)
HK (1) HK1179255A1 (pt)
MX (1) MX2012014348A (pt)
NZ (1) NZ604649A (pt)
RU (1) RU2012157469A (pt)
SG (2) SG186250A1 (pt)
TW (1) TWI482770B (pt)
WO (1) WO2011156464A1 (pt)
ZA (1) ZA201209648B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200635A1 (en) * 2014-06-25 2015-12-30 Abbvie Inc. N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
JP5237108B2 (ja) * 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物
SG182146A1 (en) * 2008-03-05 2012-07-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
PE20110830A1 (es) * 2008-12-05 2011-12-14 Abbvie Bahamas Ltd Derivados de tieno[3,2-c]piridina como inhibidores de quinasas

Also Published As

Publication number Publication date
JP2013528221A (ja) 2013-07-08
TW201202235A (en) 2012-01-16
TWI482770B (zh) 2015-05-01
CN103038239A (zh) 2013-04-10
US20140296284A1 (en) 2014-10-02
ZA201209648B (en) 2013-08-28
SG186250A1 (en) 2013-01-30
CA2802029A1 (en) 2011-12-15
AR083152A1 (es) 2013-02-06
RU2012157469A (ru) 2014-07-20
EP2580220A1 (en) 2013-04-17
HK1179255A1 (en) 2013-09-27
US8633217B2 (en) 2014-01-21
SG2014014278A (en) 2014-06-27
US20120202844A1 (en) 2012-08-09
NZ604649A (en) 2014-11-28
WO2011156464A8 (en) 2012-10-11
AU2011264902A1 (en) 2013-01-10
ES2536503T3 (es) 2015-05-26
AU2011264902B2 (en) 2015-01-29
WO2011156464A1 (en) 2011-12-15
JP5727598B2 (ja) 2015-06-03
EP2580220B1 (en) 2015-02-11
US8940759B2 (en) 2015-01-27
MX2012014348A (es) 2013-04-24
KR20130112856A (ko) 2013-10-14

Similar Documents

Publication Publication Date Title
PH12015502792A1 (en) Crystalline bromodomain inhibitors
EA201100030A1 (ru) Пиразольные соединения 436
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
EA201190296A1 (ru) Дисахариновая, дифумарово-кислая, ди-1-гидрокси-2-нафтойно-кислая и монобензойно-кислая соли 4-(диметиламино)бутил-2-(4-((2-амино-4-метил-6-(пентиламино)пиримидин-5-ил)метил)фенил)ацетата
NO20090628L (no) Pyridizinon derivativater
DK2544674T3 (da) Cdc7-kinaseinhibitorer og anvendelser deraf
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
NZ593295A (en) Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor
TN2009000446A1 (en) P70 s6 kinase inhibitors
EP2321264A4 (en) DEACETYLASEINHIBITORS AND APPLICATIONS THEREOF
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201290976A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
UA113215C2 (xx) Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
SE0403086D0 (sv) Compounds
BR112012031485A2 (pt) formas cristalinas de inibidores de quinase
EA201000889A1 (ru) Тризамещенные пиперидины в качестве ингибиторов ренина

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)